Preckler V, Espín J. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review. Value Health. 2022;25(4):666-675. https://doi.org/10.1016/j.jval.2021.11.1376 PMID:35227598 DOI: https://doi.org/10.1016/j.jval.2021.11.1376

Campillo-Artero C, Puig-Junoy J, Segú-Tolsa JL, Trapero-Bertran M. Price Models for Multi-indication Drugs: A Systematic Review. Appl Health Econ Health Policy. 2020;18(1):47-56. https://doi.org/10.1007/s40258-019-00517-z PMID:31523756 DOI: https://doi.org/10.1007/s40258-019-00517-z

Cole A, Neri M, Cookson G. Payment Models for Multi-Indication Therapies. Online https://www.ohe.org/publications/payment-models-multi-indication-therapies. (Accessed July 2022). DOI: https://doi.org/10.1016/j.jval.2021.11.680

Antonanzas F, Juárez-Castelló C, Lorente R, Rodríguez-Ibeas R. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments. PharmacoEconomics. 2019;37(12):1469-1483. https://doi.org/10.1007/s40273-019-00838-w PMID:31535280 DOI: https://doi.org/10.1007/s40273-019-00838-w

Whittal A, Jommi C, De Pouvourville G, et al. Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework - Corrigendum. Int J Technol Assess Health Care. 2022;38(1):e43. https://doi.org/10.1017/S0266462322000290PMID:35607832 DOI: https://doi.org/10.1017/S0266462322000290

Xoxi E, Rumi F, Kanavos P, et al. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems. Front Med Technol. 2022;4:888404. https://doi.org/10.3389/fmedt.2022.888404 PMID:35782579 DOI: https://doi.org/10.3389/fmedt.2022.888404

Riccaboni M, Swoboda T, Van Dyck W. Pharmaceutical net price transparency across european markets: insights from a multi-agent simulation model. Health Policy. 2022;126(6):534-540. https://doi.org/10.1016/j.healthpol.2022.03.013 PMID:35459584 DOI: https://doi.org/10.1016/j.healthpol.2022.03.013

Michaeli DT, Mills M, Kanavos P. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Appl Health Econ Health Policy. 2022;20(5):757-768. https://doi.org/10.1007/s40258-022-00737-w PMID:35821360 DOI: https://doi.org/10.1007/s40258-022-00737-w

Pani L, Cicchetti A, De Luca A, et al. Pricing for multi-indication medicines: a discussion with Italian experts. Pharmadvance 2022; 4 (2): 163-170. Online http://www.pharmadvances.com/pricing-for-multi-indication-medicines-a-discussion-with-italian-experts/. (Accessed July 2022). DOI: https://doi.org/10.36118/pharmadvances.2022.27